Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 8, 2026Breast CancerOpen Access

UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAna Gil-TorralvoMDM. Ángeles Domínguez-CejudoSMSonia Molina-Pinelo

Discussion

Loading...

Member takes

Overview

Two-phase study identifies UGT2B17 as a predictive biomarker of treatment response in HER2-positive breast cancer, suggesting enhanced patient stratification.

Key Points

  • The research aims to identify predictive biomarkers for treatment response in HER2-positive breast cancer after neoadjuvant therapy.
  • Conducted a two-phase study with 53 HER2-positive, hormone receptor–negative breast cancer patients.
  • Performed transcriptomic profiling in a discovery cohort of 13 patients to identify differentially expressed genes.
  • Validated findings using qPCR in an independent cohort of 40 patients.
  • Executed functional enrichment analysis to understand biological pathways involved.
  • Identified 6251 genes associated with treatment response, with significant roles in xenobiotic metabolism and steroid hormone biosynthesis.
  • UGT2B17 overexpression linked to resistance, showing p = 0.023, AUC = 0.699, sensitivity of 77.2%, and specificity of 64.5%.
  • UGT2B28 also identified as a predictive biomarker (p = 0.046, AUC = 0.677) but was less discriminative than UGT2B17.

Cite This Study

Gil-Torralvo et al. (2026) studied this question.

synapsesocial.com/papers/69ada873bc08abd80d5bb6edhttps://doi.org/10.1007/s12282-026-01840-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unveiling the relationship between the UGT2B gene family and neoadjuvant treatment response in patients with HER2-positive breast cancer.2024
  2. 2Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression2025
  3. 3Abstract PO3-14-05: Integration of metabolomics and transcriptomics to Reveal Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+ Breast Cancer2024
  4. 4Abstract PO1-15-05: Gene expression signature as a predictor of pathological complete response to neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab treatment in locally advanced HER2-positive breast cancer2024
  5. 5Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer2024 · 16 citations